Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1716-1725

  Perl, Alexander E ^a   Kasner, Margaret T ^b   Shank, Doris ^a   Luger, Selina M ^a   Carroll, Martin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CYTARABINE; ETOPOSIDE; HYDROXYUREA; MAMMALIAN TARGET OF RAPAMYCIN; MITOXANTRONE; RAPAMYCIN; S6 KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE GRANULOCYTIC LEUKEMIA BLAST; ADULT; AGED; ARTICLE; CELL EXPANSION; CELL SUBPOPULATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG MONITORING; DRUG RESISTANCE; DRUG SENSITIVITY; FEASIBILITY STUDY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; LEUKOCYTOSIS; LOADING DRUG DOSE; LYMPHOCYTE; MALE; MONOCYTE; MONOCYTE MACROPHAGE PRECURSOR CELL; MYELOBLAST; PHARMACODYNAMICS; PILOT STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TUMOR CELL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; PHOSPHORYLATION; PILOT PROJECTS; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84858228734     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2346     Document Type: Article

References (20)

1. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Singleagent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-76. (Pubitemid 38596280)
2. Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009;113:3938-46.
3. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7.
4. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121:396-409.
5. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, Gjertsen BT, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004;118:217-28. (Pubitemid 38962577)
6. Han L, Wierenga AT, Rozenveld-Geugien M, van de Lande K, Vellenga E, Schuringa JJ. Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS One 2009;4:e7989.
7. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008;14:335-43.
8. Lee AW, Sharp ER, O'Mahony A, Rosenberg MG, Israelski DM, Nolan GP, et al. Single-cell, phosphoepitope-specific analysis demonstratescell type- and pathway-specific dysregulation of Jak/STAT and MAPK signaling associatedwith in vivo human immunodeficiency virus type 1 infection. J Virol 2008;82:3702-12. (Pubitemid 351429946)
9. Chow S, Hedley D, Grom P, Magari R, Jacobberger JW, Shankey TV. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations. Cytometry A 2005;67:4-17. (Pubitemid 41318288)
10. Chow S, Minden MD, Hedley DW. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol 2006;34: 1183-91.
11. Woost PG, Solchaga LA, Meyerson HJ, Shankey TV, Goolsby CL, Jacobberger JW. High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow. Blood 2011;117:e131-41.
12. Marvin J, Swaminathan S, Kraker G, Chadburn A, Jacobberger J, Goolsby C. Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood 2011;117:e120-30.
13. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48.
14. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972-80. (Pubitemid 36917792)
15. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005;106:4261-8. (Pubitemid 41775935)
16. Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus andMECchemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009;15:6732-9.
17. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009;114:1618-27.
18. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-9. (Pubitemid 46594039)
19. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997;90:2863-92. (Pubitemid 27444181)
20. Hedley DW, Chow S, Goolsby C, Shankey TV. Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. Toxicol Pathol 2008;36:133-9.